Type 1 regulatory T (Tr1) cells, in addition to other regulatory cells ... Tr1 cells display high surface expression of CD49b, CCR5, CD2, CD18, CD226, and many co-inhibitory receptors such as LAG-3, ...

We describe two patients in whom malignant monoclonal T-cell lymphoproliferation developed after administration of chimeric antigen receptor (CAR) T-cell therapy with ciltacabtagene autoleucel ...

Dr. Hege joins the Board as EvolveImmune prepares to enter the clinic in mid-2025 with EVOLVE104, its lead trispecific T cell engager with integrated CD2 T cell costimulation BRANFORD, Conn., Feb. 11, ...

Dr. Hege joins the Board as EvolveImmune prepares to enter the clinic in mid-2025 with EVOLVE104, its lead trispecific T cell engager with integrated CD2 T cell costimulationBRANFORD, Conn., Feb. 11, ...

To examine the potential contribution of idelalisib to the increased risk of infection, we investigated the effects of idelalisib on the immune cell compartments of healthy donors (HDs) and CLL ...

4 Institute of Pathology and Comprehensive Cancer Center EMN, Friedrich-Alexander-Universität (FAU) Erlangen-Nürnberg and Uniklinikum Erlangen, Erlangen, Germany Objectives CD19-targeting chimeric ...

CAR T cell therapy is one of the most promising new cancer treatments to emerge in recent years. CAR T cells are engineered cancer immunotherapies that boost or hijack a person’s immune system ...

The announcement comes just a few weeks after GSK also pulled out of two other T-cell ... the CD2-26 axis," with a "pragmatic approach within synthetic lethality and tumour cell targeting ...

See a doctor who has experience with it. You’ll find dermatologists who have experience with cutaneous T-cell lymphoma at Find a Dermatologist. Click on "Filters". Select "Any condition" and choose ...

Prolonged illnesses like cancer and chronic infections often leave the immune system in a state of exhaustion, where its frontline defenders—T cells—lose their ability to function effectively.